| Number of participants achieving protective titre post‐vaccination (> 40) after immunisation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Influenza strain | Group 1. First dose n% | Total N | Group 1. Sec dose n% | Total N | Group 2. First dose n% | Total N | Group 2. Sec dose n% | Total N | P‐value |
| Hsieh 2002a | A/NC/20/99 | 5 (55.6%) | 9 | 5 (55.6%) | 9 | 3 (60%) | 5 | 3 (60%) | 5 | 0.79= NS comparing Group 1 second dose to Group 2 second dose |
| Hsieh 2002a | A/Pan/2007/99 | 2 (28.6%) | 7 | 5 (71.4%) | 7 | 0 (0%) | 3 | 1 (33.3%) | 3 | 0.35 = NS comparing Group 1 second dose to Group 2 second dose |
| Hsieh 2002a | B/Yam/166/98 | 6 (85.7%) | 7 | 6 (85.7%) | 7 | 5 (83.3%) | 6 | 5 (83.3%) | 6 | 0.73 = NS comparing Group 1 second dose to Group 2 second dose |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.